Anticoagulation in Patients with Heparin-Induced Thrombocytopenia undergoing Percutaneous Coronary Angiography and Interventions

Title: Anticoagulation in Patients with Heparin-Induced Thrombocytopenia undergoing Percutaneous Coronary Angiography and Interventions

Volume: 14 Issue: 12

Author(s): Alexander Joost, Volkhard Kurowski and Peter W. Radke

Affiliation:

Keywords: Heparin-induced-thrombocytopenia, HIT, PCI, argatroban, bivalirudin, lepirudin, danaparoid, fondaparinux

Abstract: The administration of heparins (unfractionated or fractionated) represents the current standard as anticoagulant treatment during percutaneous coronary intervention in different clinical settings (elective cases and acute coronary syndrome). Since the incidence of heparin-induced thrombocytopenia (HIT) is expected to range between 0.1 and 5%, the application of an appropriate anticoagulant agent has become a mandatory issue. This review will provide current pathophysiological insights of HIT as well as contemporary alternative anticoagulant strategies during PCI in patients with or at risk of HIT.

Cite this article as:

Joost Alexander, Kurowski Volkhard and Radke W. Peter, Anticoagulation in Patients with Heparin-Induced Thrombocytopenia undergoing Percutaneous Coronary Angiography and Interventions, Current Pharmaceutical Design 2008; 14(12) . https://dx.doi.org/10.2174/138161208784246126